Technical advancements have substantially extended the indications for surgery in diabetic retinopathy (DR) during the last 40 years, from the traditional indications including non-clearing vitreous hemorrhage, traction retinal detachment (RD), and traction-rhegmatogenous RD, to epiretinal membrane (ERM), vitreomacular traction, diffuse macular edema, neovascular glaucoma, and anterior hyaloid fibrovascular proliferation. The goals of vitreoretinal surgery in DR are multiple: clearing media opacities, release of traction (anteroposterior and/or tangential), segmentation and/or removal of traction bands, peeling of ERMs, hemostasis, laser photocoagulation, and tamponade of retinal breaks with gas or silicone oil. The best management is achieved with integrated care provided by physicians with expertise in medical management of diabetes and surgical care of DR. In this chapter, the indications for surgery, preoperative considerations, surgical techniques, and complications, together with their management, will be discussed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000459702 | DOI Listing |
Obes Surg
January 2025
Ziekenhuis Groep Twente, Almelo, Netherlands.
Background: This study aimed to create a comprehensive Core Outcome Set (COS) for assessing the long-term outcome (≥ 5 years) after Metabolic Bariatric Surgery (MBS), through the use of the Delphi method.
Methods: The study utilized a three-phase approach. In Phase 1, a long list of items was identified through a literature review and expert input, forming the basis for an online Delphi survey.
Rev Gastroenterol Peru
January 2025
Hospital Nacional Edgardo Rebagliati Martins, Lima, Perú; Universidad San Ignacio de Loyola, Lima, Perú.
Unlabelled: Endoscopic submucosal dissection (ESD) is the technique of choice in the management of early gastric cancer. Recently, it is also considered as an absolute indication in selected cases of early undifferentiated gastric cancer (U-EGC).
Objectives: In the present study, the first documented cases of ESD in patients with U-EGC are presented and analyzed.
J Coll Physicians Surg Pak
January 2025
Department of Obstetrics and Gynaecology, Health Sciences University, Bursa Yuksek Ihtisas Training and Research Hospital,
Bursa, Turkiye.
Objective: To compare the inflammatory markers between therapeutic and emergency cerclage and assess the predictive role of inflammatory markers for the latency period.
Study Design: Descriptive study. Place and Duration of the Study: Department of Obstetrics and Gynaecology, Bursa Yuksek Ihtisas Training and Research Hospital, Turkiye, from January 2016 to September 2022.
J Pediatr Surg
January 2025
Chelsea & Westminster Hospital and Imperial College Hospitals (West London Children's Hospital Alliance), Imperial College London, United Kingdom. Electronic address:
Introduction: There is equipoise among pediatric urologists regarding endoscopic versus surgical intervention for symptomatic Grade 4-5 Vesicoureteric Reflux (VUR), particularly in infancy. Our aim was to assess outcomes of first-line endoscopic treatment in all cases of symptomatic Grade 4-5 VUR and we hypothesised that using endoscopic Dx/HA as first line management for primary VUR would obviate the need for ureteric reimplantation in the majority of cases.
Methods: Retrospective single-surgeon analysis of consecutive patients with primary Grade 4-5 VUR over 15 years.
J Bone Miner Res
January 2025
Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical University, Fukushima-city, Fukushima, Japan.
This study analyzed the association of romosozumab, a human monoclonal antibody with bone-forming and bone resorption-inhibiting effects, and bisphosphonates with the development of cardiovascular disease among patients with osteoporosis. A new-user design was employed to address selection bias, and instrumental variable analysis was used to address confounding by indication. Japanese patients aged ≥40 years, diagnosed with osteoporosis or experienced a fragility fracture, were admitted to medical facilities covered by a commercial administrative claims database, and newly prescribed romosozumab or bisphosphonates after the commercialization of romosozumab in Japan (March 4, 2019) were included based on verification of a 180-day washout period.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!